Pfizer’s ongoing phase 3 trial studying its COVID-19 vaccine among children between 6 months and 4 years old continued to prove efficacy but showed it has slipped from about 80 percent to 73.2 percent.
Read the full post on Becker's Hospital Review - Healthcare News
